Question for written answer - European Parliament

?Question for written answer E-004833/2020to the CommissionRule 138Gerolf Annemans (ID)Subject:Protection from liability claims related to COVID-19 vaccine being developed at the University of OxfordThe Commission has reportedly struck a deal with the AstraZeneca pharmaceutical company making 300 million doses of vaccine available to signatory Member States. The vaccine is still being developed at the University of Oxford.In return for guaranteeing such large quantities of vaccine to the Member States, the company is to receive substantial product development funding approved by the Commission. Apparently, it has also stipulated protection from future liability claims related to any serious side-effects of the COVID-19 vaccine that might appear down the line.1.Is it true that that the Commission has made a deal to guarantee the availability of millions of doses of the vaccine being developed at the University of Oxford? Can it indicate the amounts and quantities involved?2.What is the situation regarding (exemption from) liability under the agreement?3.How would any exemption chime with the provisions of the EU directive on product liability? ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download